CoChat
Sign Up
Cited by 373

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

Lu, Qiang, Kou, Dongquan, Lou, Shenghan, Ashrafizadeh, Milad, Aref, Amir Reza, Canadas, Israel, Tian, Yu, Niu, Xiaojia, Wang, Yuzhuo, Torabian, Pedram, Wang, Lingzhi, Sethi, Gautam, Tergaonkar, Vinay, Tay, Franklin, Yuan, Zhennan, Han, Peng·2024·Journal of Hematology & Oncology
DOI 10.1186/s13045-024-01535-8PMC PMC10986145
Open this paper in CoChat — free account

Abstract

Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in the clinical delivery of immunomodulatory compounds. The tumor microenvironment (TME), comprising macrophages, fibroblasts, and immune cells, plays a crucial role in immune response modulation. Nanoparticles, engineered to reshape the TME, have shown promising results in enhancing immunotherapy by facilitating targeted delivery and immune modulation. These nanoparticles can suppress fibroblast activation, promote M1 macrophage polarization, aid dendritic cell maturation, and encourage T cell infiltration. Biomimetic nanoparticles further enhance immunotherapy by increasing the internalization of immunomodulatory agents in immune cells such as dendritic cells. Moreover, exosomes, whether naturally secreted by cells in the body or bioengineered, have been explored to regulate the TME and immune-related cells to affect cancer immunotherapy. Stimuli-responsive nanocarriers, activated by pH, redox, and light conditions, exhibit the potential to accelerate immunotherapy. The co-application of nanoparticles with immune checkpoint inhibitors is an emerging strategy to boost anti-tumor immunity. With their ability to induce long-term immunity, nanoarchitectures are promising structures in vaccine development. This review underscores the critical role of nanoparticles in overcoming current challenges and driving the advancement of cancer immunotherapy and TME modification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-024-01535-8

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 An overview of using nanoparticles in cancer immunotherapy. The nanoparticles circulate in blood, and upon reaching the tumor site, they re-educate several tumor microenvironment components, including cancer-associated fibroblasts and tumor-associated macrophages, to finally activate the immune system. Moreover, nanoparticles can stimulate immunogenic cell death to enhance the maturation of dendritic cells for the activation of immune cells, such as T cells, to enhance cancer immunotherapy. The co-application of nanoparticles with immune checkpoint inhibitors, such as PD-L1 blockers, can augment the potential of cancer immunotherapy
Fig. 1 An overview of using nanoparticles in cancer immunotherapy. The nanoparticles circulate in blood, and upon reaching the tumor site, they re-educate several tumor microenvironment components, including cancer-associated fibroblasts and tumor-associated macrophages, to finally activate the immune system. Moreover, nanoparticles can stimulate immunogenic cell death to enhance the maturation of dendritic cells for the activation of immune cells, such as T cells, to enhance cancer immunotherapy. The co-application of nanoparticles with immune checkpoint inhibitors, such as PD-L1 blockers, can augment the potential of cancer immunotherapyCC BY · PubMed Central
Fig. 2 Cellular components that influence the tumor microenvironment (TME). Interactions within the TME play a crucial role in accelerating cancer progression. Cancer cells activate the PD-L1/PD-1 axis, leading to T cell exhaustion and impairment of T cell function. In addition, cancer cell-secreted exosomes that carry PD-1 contribute to T cell dysfunction, reducing proliferation and hindering proper function. Natural killer cells counteract tumorigenesis by secreting perforin and granular enzymes. Increased infiltration of Treg cells in the TME secretes TGF-β, inducing fibroblast transformation into cancer-associated fibroblasts (CAFs), promoting extracellular matrix deposition, and causing T cell dysfunction. Myeloid-derived suppressor cells (MDSCs) induce Treg cell formation in the TME through the secretion of PGE-2, IL-10, and TGF-β. Regulatory T cells (Treg), in turn, suppress the function of dendritic cells (DCs) by secreting perforin, leading to DC cell apoptosis. M2-polarized macrophages secrete TGF-β and IL-10, disrupting DC cell function. The interaction between endothelial cells and cancer cells results in angiogenesis, further enhancing cancer progression (created by Biorender.com)
Fig. 2 Cellular components that influence the tumor microenvironment (TME). Interactions within the TME play a crucial role in accelerating cancer progression. Cancer cells activate the PD-L1/PD-1 axis, leading to T cell exhaustion and impairment of T cell function. In addition, cancer cell-secreted exosomes that carry PD-1 contribute to T cell dysfunction, reducing proliferation and hindering proper function. Natural killer cells counteract tumorigenesis by secreting perforin and granular enzymes. Increased infiltration of Treg cells in the TME secretes TGF-β, inducing fibroblast transformation into cancer-associated fibroblasts (CAFs), promoting extracellular matrix deposition, and causing T cell dysfunction. Myeloid-derived suppressor cells (MDSCs) induce Treg cell formation in the TME through the secretion of PGE-2, IL-10, and TGF-β. Regulatory T cells (Treg), in turn, suppress the function of dendritic cells (DCs) by secreting perforin, leading to DC cell apoptosis. M2-polarized macrophages secrete TGF-β and IL-10, disrupting DC cell function. The interaction between endothelial cells and cancer cells results in angiogenesis, further enhancing cancer progression (created by Biorender.com)CC BY · PubMed Central
Fig. 3 The impact of nanoparticles on macrophages, showcasing their potential to re-educate and impede cancer progression. These nanoparticles effectively target key mechanisms associated with the M2 polarization of tumor-associated macrophages. They inhibit CD44/SIRPα, CS1R, and MAPK, prompting the M1 polarization of macrophages. Additionally, nanocarriers activate the TLR4/MyD88 axis, contributing to increased M1 polarization of the tumor-associated macrophages. The nanoparticles further induce ferroptosis and photodynamic therapy, disrupting the polarization of these macrophages into the M2 phenotype (Created by Biorender.com)
Fig. 3 The impact of nanoparticles on macrophages, showcasing their potential to re-educate and impede cancer progression. These nanoparticles effectively target key mechanisms associated with the M2 polarization of tumor-associated macrophages. They inhibit CD44/SIRPα, CS1R, and MAPK, prompting the M1 polarization of macrophages. Additionally, nanocarriers activate the TLR4/MyD88 axis, contributing to increased M1 polarization of the tumor-associated macrophages. The nanoparticles further induce ferroptosis and photodynamic therapy, disrupting the polarization of these macrophages into the M2 phenotype (Created by Biorender.com)CC BY · PubMed Central
Fig. 4 Nanoparticles orchestrating immune cells and cancer-associated fibroblasts (CAFs). Nanoparticles elevate antigen presentation via MHC-I and MHC-II, stimulating CD4+ and CD8+ T cells, thereby facilitating cancer immunotherapy. The nanostructures amplify Dectin-2 and TLR-4 levels, fostering TH17 responses for effective cancer immunotherapy. Additionally, they boost dendritic cell maturation and, through the delivery of anti-miR-21, induce polarization of macrophages into the M1 phenotype. The nanoparticles’ downregulation of osteopontin in CAFs disrupts cancer progression. Moreover, these nanoparticles suppress Treg cells, preventing immunosuppression (Created by Biorender.com)
Fig. 4 Nanoparticles orchestrating immune cells and cancer-associated fibroblasts (CAFs). Nanoparticles elevate antigen presentation via MHC-I and MHC-II, stimulating CD4+ and CD8+ T cells, thereby facilitating cancer immunotherapy. The nanostructures amplify Dectin-2 and TLR-4 levels, fostering TH17 responses for effective cancer immunotherapy. Additionally, they boost dendritic cell maturation and, through the delivery of anti-miR-21, induce polarization of macrophages into the M1 phenotype. The nanoparticles’ downregulation of osteopontin in CAFs disrupts cancer progression. Moreover, these nanoparticles suppress Treg cells, preventing immunosuppression (Created by Biorender.com)CC BY · PubMed Central
Fig. 5 Biomimetic nanoparticles may be developed by the extraction of membranes from red blood cells, cancer cells, TAMs and CAFs. These modifications improve the potential of nanoparticles in cancer immunotherapy. Biomimetic nanoparticles may be utilized for drug and gene delivery by improving stealth properties. They demonstrate prolonged blood circulation and can induce maturation of dendritic cells, increase infiltration of CD4+ and CD8+ T cells, and cause immunogenic cell death. (Created by Biorender.com)
Fig. 5 Biomimetic nanoparticles may be developed by the extraction of membranes from red blood cells, cancer cells, TAMs and CAFs. These modifications improve the potential of nanoparticles in cancer immunotherapy. Biomimetic nanoparticles may be utilized for drug and gene delivery by improving stealth properties. They demonstrate prolonged blood circulation and can induce maturation of dendritic cells, increase infiltration of CD4+ and CD8+ T cells, and cause immunogenic cell death. (Created by Biorender.com)CC BY · PubMed Central
Fig. 6 Stimuli-responsive nanocarriers in cancer immunotherapy. Nanoparticles that respond to pH, redox, or light can release cargo to induce apoptosis, DNA damage, and regulation of molecular pathways. Moreover, stimuli-responsive nanocarriers stimulate immunogenic cell death to increase dendritic cell maturation. They migrate into lymph nodes and increase activation of T cells
Fig. 6 Stimuli-responsive nanocarriers in cancer immunotherapy. Nanoparticles that respond to pH, redox, or light can release cargo to induce apoptosis, DNA damage, and regulation of molecular pathways. Moreover, stimuli-responsive nanocarriers stimulate immunogenic cell death to increase dendritic cell maturation. They migrate into lymph nodes and increase activation of T cellsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 575

  1. Liu Y, et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):104. · DOI
  2. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104. · DOI
  3. Webster RM. The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov. 2014;13(12):883–4. · DOI
  4. Zhang Q, et al. Immune and Clinical features of CD96 expression in Glioma by in silico analysis. Front Bioeng Biotechnol. 2020;8:592. · DOI
  5. Galipeau J, Sensébé L. Mesenchymal stromal cells: Clinical challenges and Therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–33. · DOI · Paper page
  6. Liotta F, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing notch signaling. Stem Cells. 2008;26(1):279–89. · DOI
  7. Barkal AA, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392–6. · DOI
  8. Barkal AA, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19(1):76–84. · DOI
  9. Lin H, et al. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer Cell. 2021;39(4):480–e4936. · DOI
  10. Theruvath J, et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med. 2022;28(2):333–44. · DOI
  11. Gardner A, de Mingo Á, Pulido, Ruffell B. Dendritic cells and their role in Immunotherapy. Front Immunol. 2020;11:924. · DOI
  12. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. · DOI · Paper page
  13. Nakayama M. Antigen Presentation by MHC-Dressed cells. Front Immunol. 2014;5:672.
  14. Lin A, Loré K. Granulocytes: New members of the Antigen-presenting cell family. Front Immunol. 2017;8:1781. · DOI
  15. Broz ML, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638–52. · DOI · Paper page
  16. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369–82. · DOI
  17. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462–72. · DOI · Paper page
  18. Sánchez-Paulete AR, et al. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 monoclonal antibodies requires BATF3-Dependent dendritic cells. Cancer Discov. 2016;6(1):71–9. · DOI
  19. Roberts EW, et al. Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for Tumor Antigen Trafficking and priming of T cell immunity in Melanoma. Cancer Cell. 2016;30(2):324–36. · DOI
  20. Salmon H, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the Tumor Site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–38. · DOI
  21. de Pulido M. TIM-3 regulates CD103(+) dendritic cell function and response to chemotherapy in breast Cancer. Cancer Cell. 2018;33(1):60–74.e6. · DOI · Paper page
  22. Xia Y, et al. Engineering macrophages for Cancer Immunotherapy and Drug Delivery. Adv Mater. 2020;32(40):e2002054. · DOI · Paper page
  23. Gao J, Liang Y, Wang L. Shap Polarization Tumor-Associated Macrophages Cancer Immunotherapy Front Immunol. 2022;13:888713.
  24. Kumari N, Choi SH. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J Exp Clin Cancer Res. 2022;41(1):68. · DOI
  25. Li L, Ma SR, Yu ZL. Targeting the lipid metabolic reprogramming of tumor-associated macrophages: a novel insight into cancer immunotherapy. Cell Oncol (Dordr); 2023. · DOI
  26. Pei L, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):29. · DOI
  27. Zhang H, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159. · DOI
  28. Thiery J. Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions. Explor Target Antitumor Ther. 2022;3(5):598–629. · DOI
  29. Wang Q, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023;12(10):11149–65. · DOI
  30. Han S et al. Tumor Microenvironment Regulation and Cancer Targeting Therapy based on nanoparticles. J Funct Biomater, 2023. 14(3). · DOI
  31. Li Z, Yin P. Tumor microenvironment diversity and plasticity in cancer multidrug resistance. Biochim Biophys Acta Rev Cancer. 2023;1878(6):188997. · DOI
  32. Yang R, et al. Tumor microenvironment responsive metal nanoparticles in cancer immunotherapy. Front Immunol. 2023;14:1237361. · DOI
  33. Zhang Z, et al. Involvement of inflammasomes in tumor microenvironment and tumor therapies. J Hematol Oncol. 2023;16(1):24. · DOI
  34. Jin HR, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16(1):103. · DOI
  35. Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421–33. · DOI
  36. Lin MJ, et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3(8):911–26. · DOI
  37. Beck JD, et al. mRNA therapeutics in cancer immunotherapy. Mol Cancer. 2021;20(1):69. · DOI · Paper page
  38. Siminiak N, et al. Immunotherapy in Ovarian Cancer. Arch Immunol Ther Exp (Warsz). 2022;70(1):19. · DOI
  39. Mauricio D, et al. Immunotherapy in Cervical Cancer. Curr Oncol Rep. 2021;23(6):61. · DOI
  40. Bockorny B, Grossman JE, Hidalgo M. Facts and hopes in Immunotherapy of Pancreatic Cancer. Clin Cancer Res. 2022;28(21):4606–17. · DOI
  41. Yang M, et al. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater. 2021;6(7):1973–87.
  42. Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials. 2018;156:217–37. · DOI
  43. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–92.
  44. Prabhakar U, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73(8):2412–7. · DOI
  45. Yang S, Gao H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol Res. 2017;126:97–108. · DOI · Paper page
  46. Chen Q, et al. Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics. Trends Pharmacol Sci. 2018;39(1):59–74. · DOI
  47. Li M, et al. Nanoparticles designed to regulate tumor microenvironment for cancer therapy. Life Sci. 2018;201:37–44. · DOI
  48. Guo B, et al. Cuproptosis Induced by ROS responsive nanoparticles with Elesclomol and Copper Combined with αPD-L1 for enhanced Cancer Immunotherapy. Adv Mater. 2023;35(22):e2212267. · DOI
  49. Wang-Bishop L, et al. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy. Sci Immunol. 2023;8(83):eadd1153. · DOI
  50. Ding B, et al. ZIF-8 nanoparticles evoke pyroptosis for high-efficiency Cancer Immunotherapy. Angew Chem Int Ed Engl. 2023;62(10):e202215307. · DOI
  51. Liu J et al. Ultrathin clay nanoparticles-mediated mutual reinforcement of ferroptosis and Cancer immunotherapy. Adv Mater, 2023: p. e2309562. · DOI
  52. Huang A, et al. Engineered apoptosis-bioinspired nanoparticles initiate Immune Cascade for Cancer Immunotherapy of Malignant ascites. ACS Appl Mater Interfaces. 2023;15(8):10371–82. · DOI
  53. Liu D et al. Tumor Microenvironment-Responsive nanoparticles amplifying STING Signaling Pathway for Cancer Immunotherapy. Adv Mater, 2023: p. e2304845. · DOI
  54. Sun Y, et al. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer. Eur J Pharm Sci. 2023;185:106427. · DOI
  55. Liu C, et al. Microfluidic sonication to assemble Exosome membrane-coated nanoparticles for Immune evasion-mediated targeting. Nano Lett. 2019;19(11):7836–44. · DOI
  56. Li M et al. Signaling pathways in macrophages: molecular mechanisms and therapeutic targets MedComm (2020), 2023;4(5):e349. · DOI
  57. Ginhoux F, Guilliams M. Tissue-Resident Macrophage Ontogeny and Homeostasis. Immunity. 2016;44(3):439–49. · DOI · Paper page
  58. Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol. 2014;5:514. · DOI · Paper page
  59. Zhan C et al. Antitumor therapy for breast cancer: focus on tumor-associated macrophages and nanosized drug delivery systems. Cancer Med, 2023. · DOI
  60. Wang N, et al. Research trends in pharmacological modulation of tumor-associated macrophages. Clin Transl Med. 2021;11(1):e288. · DOI
  61. Wang J, et al. Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019;8(10):4709–21. · DOI
  62. Munir MT et al. Tumor-Associated macrophages as multifaceted regulators of breast tumor growth. Int J Mol Sci, 2021. 22(12). · DOI
  63. Qiu SQ, et al. Tumor-associated macrophages in breast cancer: innocent bystander or important player? Cancer Treat Rev. 2018;70:178–89. · DOI
  64. Wang C, et al. Macrophage balance fraction determines the degree of immunosuppression and metastatic ability of breast cancer. Int Immunopharmacol. 2021;97:107682. · DOI
  65. Steenbrugge J, et al. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer. J Exp Clin Cancer Res. 2018;37(1):191. · DOI
  66. Shu Y, Cheng P. Targeting tumor-associated macrophages for cancer immunotherapy Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2020;1874(2):188434. · DOI
  67. Nascimento C, et al. Reprogramming of tumor-associated macrophages by polyaniline-coated iron oxide nanoparticles applied to treatment of breast cancer. Int J Pharm. 2023;636:122866. · DOI
  68. Shang Y, et al. Bioengineered Nanospores selectively blocking LC3-Associated phagocytosis in Tumor-Associated macrophages Potentiate Antitumor Immunity. ACS Nano. 2023;17(11):10872–87. · DOI
  69. Liu Y, et al. Multifunctional nanoparticles inhibit tumor and tumor-associated macrophages for triple-negative breast cancer therapy. J Colloid Interface Sci. 2024;657:598–610. · DOI
  70. Liang DS, et al. Targeted delivery of pexidartinib to tumor-associated macrophages via legumain-sensitive dual-coating nanoparticles for cancer immunotherapy. Colloids Surf B Biointerfaces. 2023;226:113283. · DOI
  71. Sun H, et al. The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer. Cell Death Dis. 2022;13(10):874. · DOI
  72. Gu J, et al. The role of PKM2 nuclear translocation in the constant activation of the NF-κB signaling pathway in cancer-associated fibroblasts. Cell Death Dis. 2021;12(4):291. · DOI
  73. Bu L, et al. Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. Oncogene. 2019;38(25):4887–901. · DOI
  74. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–98. · DOI · Paper page
  75. Kobayashi H, et al. Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2019;16(5):282–95. · DOI
  76. Zhang T, et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 2022;13(10):897. · DOI
  77. Biffi G, et al. IL1-Induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9(2):282–301. · DOI · Paper page
  78. Elyada E, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals Antigen-Presenting Cancer-Associated fibroblasts. Cancer Discov. 2019;9(8):1102–23. · DOI · Paper page
  79. Fang Z, et al. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun. 2023;43(1):3–41. · DOI
  80. Ai W, et al. Modulation of cancer-associated fibroblasts by nanodelivery system to enhance efficacy of tumor therapy. Nanomed (Lond). 2023;18(15):1025–39. · DOI
  81. Geng S, et al. Safe engineering of cancer-associated fibroblasts enhances checkpoint blockade immunotherapy. J Control Release. 2023;356:272–87. · DOI
  82. Jian C et al. Biomimetic Nanoplatform for Dual-Targeted Clearance of Activated and Senescent Cancer-Associated Fibroblasts to Improve Radiation Resistance in Breast Cancer Small, 2024: p. e2309279. · DOI · Paper page
  83. Hu M, et al. Salvianolic acid B-loaded polydopamine-modified hollow mesoporous organic silica nanoparticles for treatment of breast cancer metastasis via suppressing cancer-associated fibroblasts. Eur J Pharm Sci. 2024;192:106641. · DOI
  84. Hinshaw DC, Shevde LA. The Tumor Microenvironment innately modulates Cancer Progression. Cancer Res. 2019;79(18):4557–66. · DOI · Paper page
  85. Wang J, et al. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8 + lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med. 2014;12:7. · DOI
  86. Deniset JF, Kubes P. Recent Adv Underst Neutrophils F1000Res. 2016;5:2912.
  87. Uribe-Querol E, Rosales C. Neutrophils in Cancer: two sides of the same Coin. J Immunol Res. 2015;2015:983698. · DOI
  88. Cools-Lartigue J, et al. Neutrophil extracellular traps in cancer progression. Cell Mol Life Sci. 2014;71(21):4179–94. · DOI
  89. Jin W, et al. Tumor-infiltrating NETs predict postsurgical survival in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26(2):635–43. · DOI
  90. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012;33(5):949–55. · DOI
  91. Demers M, et al. Priming of neutrophils toward NETosis promotes tumor growth. Oncoimmunology. 2016;5(5):e1134073. · DOI · Paper page
  92. He M, et al. Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma. Oncoimmunology. 2016;5(10):e1219828. · DOI
  93. Schauer C, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med. 2014;20(5):511–7. · DOI · Paper page
  94. Ralph SJ, Reynolds MJ. Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors. Cancer Immunol Immunother. 2023;72(3):527–42. · DOI
  95. Huntington ND, Cursons J, Rautela J. The cancer–natural killer cell immunity cycle. Nat Rev Cancer. 2020;20(8):437–54. · DOI
  96. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007;7(9):703–14. · DOI
  97. Pfefferle A, et al. Intra-lineage plasticity and functional reprogramming maintain natural killer cell repertoire diversity. Cell Rep. 2019;29(8):2284–e22944. · DOI
  98. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214:56–72. · DOI
  99. Gil M, Kim KE. Interleukin-18 is a prognostic biomarker correlated with CD8 + T cell and natural killer cell infiltration in skin cutaneous melanoma Journal of clinical medicine, 2019;8(11):1993. · DOI
  100. Cursons J, et al. A gene signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma patients. Cancer Immunol Res. 2019;7(7):1162–74. · DOI
  101. Li B et al. Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit. JCI Insight, 2020. 5(9). · DOI
  102. Ran GH, et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct Target Therapy. 2022;7(1):205. · DOI
  103. Scoville SD, Freud AG, Caligiuri MA. Model Hum Nat Killer Cell Dev Era Innate Lymphoid Cells Front Immunol. 2017;8:360.
  104. Stokic-Trtica V, Diefenbach A, Klose CSN. NK Cell Dev Times Innate Lymphoid Cell Divers Front Immunol. 2020;11:813.
  105. Vivier E, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174(5):1054–66. · DOI
  106. Freud AG, et al. The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity. 2017;47(5):820–33. · DOI
  107. Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016;16(5):310–20. · DOI
  108. Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends Immunol. 2013;34(12):573–82. · DOI
  109. Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol. 2017;31:37–54. · DOI
  110. Hammer Q, Rückert T, Romagnani C. Natural killer cell specificity for viral infections. Nat Immunol. 2018;19(8):800–8. · DOI
  111. Björkström NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nat Rev Immunol. 2022;22(2):112–23. · DOI
  112. Li Y, et al. Natural killer cells: friend or foe in metabolic diseases? Front Immunol. 2021;12:614429. · DOI
  113. Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–18. · DOI
  114. Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022;21(8):559–77. · DOI
  115. Pockley AG, Vaupel P, Multhoff G. NK cell-based therapeutics for lung cancer. Expert Opin Biol Ther. 2020;20(1):23–33. · DOI
  116. Muntasell A, et al. NK Cell infiltrates and HLA Class I expression in primary HER2(+) breast Cancer Predict and Uncouple Pathological Response and Disease-free survival. Clin Cancer Res. 2019;25(5):1535–45. · DOI
  117. Liu P, Chen L, Zhang H. Natural killer cells in Liver Disease and Hepatocellular Carcinoma and the NK cell-based immunotherapy. J Immunol Res. 2018;2018:p1206737. · DOI
  118. Ali TH, et al. Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun. 2014;5:5639. · DOI
  119. Terrén I et al. NK Cell-based immunotherapy in renal cell carcinoma. Cancers (Basel), 2020. 12(2). · DOI
  120. Lim SA, et al. Lipid metabolism in T cell signaling and function. Nat Chem Biol. 2022;18(5):470–81. · DOI
  121. Ando M, et al. Memory T cell, exhaustion, and tumor immunity. Immunological Med. 2020;43(1):1–9. · DOI
  122. Franco F, et al. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metabolism. 2020;2(10):1001–12. · DOI
  123. Douka S, et al. Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells. J Control Release. 2023;361:455–69. · DOI
  124. Shamalov K, et al. Noninvasive Tracking of Natural Killer cells using gold nanoparticles. ACS Omega. 2021;6(43):28507–14. · DOI
  125. Kim KS, et al. Cationic nanoparticle-mediated activation of natural killer cells for Effective Cancer Immunotherapy. ACS Appl Mater Interfaces. 2020;12(51):56731–40. · DOI
  126. Sun X, et al. Acid-switchable nanoparticles induce self-adaptive aggregation for enhancing antitumor immunity of natural killer cells. Acta Pharm Sin B. 2023;13(7):3093–105. · DOI
  127. Liu GW, et al. Lipid nanoparticles for nucleic acid delivery to endothelial cells. Pharm Res. 2023;40(1):3–25. · DOI
  128. Félétou M. Integrated Systems Physiology: from molecule to function to Disease, in The endothelium: part 1: multiple functions of the endothelial cells—focus on endothelium-derived Vasoactive mediators. 2011, Morgan & Claypool Life Sciences copyright © 2011 by Morgan & Claypool Life Sciences Publishers.: San Rafael (CA). · DOI
  129. Stoltz JF, et al. Introduction to endothelial cell biology. Clin Hemorheol Microcirc. 2007;37(1–2):5–8.
  130. Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol. 2013;304(12):H1585–97. · DOI
  131. Maroney SA, Mast AE. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci. 2008;38(1):9–14. · DOI
  132. Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood. 2014;124(10):1553–62. · DOI · Paper page
  133. Bremnes RM, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6(1):209–17. · DOI · Paper page
  134. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316(8):1324–31. · DOI
  135. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16(8):717–27. · DOI
  136. Dillekås H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019;8(12):5574–6. · DOI
  137. Khorana AA, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4. · DOI
  138. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862–71. · DOI
  139. Preuss SF, Grieshober D, Augustin HG. Systemic Reprogramming Endothelial cell Signal Metastasis cachexia Physiol. 2023;38(4):189–202.
  140. Eilken HM, et al. Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1. Nat Commun. 2017;8(1):1574. · DOI
  141. Zimmermann KW. Der Feinere Bau Der Blutcapillaren. Z für Anatomie und Entwicklungsgeschichte. 1923;68:29–109. · DOI
  142. Schrimpf C, et al. The role of pericyte detachment in vascular rarefaction. J Vasc Res. 2014;51(4):247–58. · DOI
  143. Hirschi KK, D’Amore PA. Pericytes in the microvasculature. Cardiovascular Res. 1996;32(4):687–98. · DOI
  144. Díaz-Flores L, et al. Microvascular pericytes, a review of their morphological and functional characteristics. Histology and histopathology; 1991.
  145. Birbrair A, et al. How plastic are pericytes? Stem Cells Dev. 2017;26(14):1013–9. · DOI
  146. Birbrair A, et al. Pericytes at the intersection between tissue regeneration and pathology. Clin Sci. 2015;128(2):81–93. · DOI
  147. Picoli CC et al. Pericytes cross-talks within the tumor microenvironment Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2021;1876(2):188608. · DOI
  148. Jiang Z et al. Pericytes in the tumor microenvironment. Cancer Lett, 2023: p. 216074. · DOI
  149. Chen Z, Xu XH, Hu J. Role of pericytes in angiogenesis: focus on cancer angiogenesis and anti-angiogenic therapy. Neoplasma. 2016;63(2):173–82.
  150. Hong CL, et al. CD248 regulates wnt signaling in Pericytes to Promote Angiogenesis and Tumor Growth in Lung Cancer. Cancer Res. 2022;82(20):3734–50. · DOI
  151. Meng YM, et al. Hexokinase 2-driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities. Nat Commun. 2021;12(1):6011. · DOI
  152. Dasgupta S, et al. RGS5-TGFβ-Smad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth. Cell Death Differ. 2021;28(11):3052–76. · DOI
  153. Pillay J, et al. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol Life Sci. 2013;70(20):3813–27. · DOI
  154. Rodriguez PC, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553–60. · DOI
  155. Youn JI, et al. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91(1):167–81. · DOI
  156. Kumar V, et al. The nature of myeloid-derived suppressor cells in the Tumor Microenvironment. Trends Immunol. 2016;37(3):208–20. · DOI · Paper page
  157. Condamine T, et al. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. 2015;66:97–110. · DOI
  158. Condamine T et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol, 2016. 1(2). · DOI
  159. Hossain F, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances Cancer therapies. Cancer Immunol Res. 2015;3(11):1236–47. · DOI
  160. Zhou J, et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 2018;67(5):931–44. · DOI
  161. Wu C, et al. Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment. Nanomedicine. 2019;16:126–37. · DOI
  162. Ding M, et al. Augmenting immunogenic cell death and alleviating myeloid-derived suppressor cells by Sono-Activatable Semiconducting Polymer Nanopartners for Immunotherapy. Adv Mater. 2023;35(33):e2302508. · DOI
  163. Zuo H, et al. Circumventing myeloid-derived suppressor cell-mediated immunosuppression using an oxygen-generated and -economized nanoplatform. ACS Appl Mater Interfaces. 2020;12(50):55723–36. · DOI
  164. Habanjar O et al. Crosstalk of inflammatory cytokines within the breast Tumor Microenvironment. Int J Mol Sci, 2023. 24(4). · DOI
  165. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27–37. · DOI
  166. Raman D, Sobolik-Delmaire T, Richmond A. Chemokines in health and disease. Exp Cell Res. 2011;317(5):575–89. · DOI
  167. Bachelerie F, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014;66(1):1–79. · DOI
  168. Mélik-Parsadaniantz S, Rostène W. Chemokines and neuromodulation. J Neuroimmunol. 2008;198(1–2):62–8. · DOI
  169. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36(5):705–16. · DOI
  170. Kaneko N, et al. The role of interleukin-1 in general pathology. Inflamm Regen. 2019;39:12. · DOI
  171. Akdis M et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases J Allergy Clin Immunol, 2011;127(3):701 – 21.e1-70. · DOI
  172. Shin E, Koo JS. The role of Adipokines and bone marrow adipocytes in breast Cancer bone metastasis. Int J Mol Sci, 2020. 21(14). · DOI
  173. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015;64(1):131–45. · DOI
  174. Mancuso P. The role of adipokines in chronic inflammation. Immunotargets Ther. 2016;5:47–56. · DOI
  175. Barchetta I, et al. Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. J Endocrinol Invest. 2019;42(11):1257–72. · DOI · Paper page
  176. Nehme R et al. Targeting adiponectin in breast Cancer. Biomedicines, 2022. 10(11). · DOI
  177. Artac M, Altundag K. Leptin and breast cancer: an overview. Med Oncol. 2012;29(3):1510–4. · DOI
  178. Ferrer I, et al. Transforming growth factor-alpha (TGF-alpha) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain. Prog Neurobiol. 1996;49(2):99–123. · DOI
  179. MaruYama T, Chen W, Shibata H. TGF-β Cancer Immunotherapy Biol Pharm Bull. 2022;45(2):155–61. · DOI
  180. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258–67. · DOI · Paper page
  181. Schroder K, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163–89. · DOI · Paper page
  182. Peng S, et al. Tumor-microenvironment-responsive nanomedicine for enhanced Cancer Immunotherapy. Adv Sci (Weinh). 2022;9(1):e2103836. · DOI
  183. Mu J, et al. Development of endogenous enzyme-responsive nanomaterials for theranostics. Chem Soc Rev. 2018;47(15):5554–73. · DOI
  184. Hu J, Zhang G, Liu S. Enzyme-responsive polymeric assemblies, nanoparticles and hydrogels. Chem Soc Rev. 2012;41(18):5933–49. · DOI
  185. Shahriari M, et al. Enzyme responsive drug delivery systems in cancer treatment. J Control Release. 2019;308:172–89. · DOI
  186. Qiu N, et al. Esterase-activated charge-reversal polymer for fibroblast-exempt Cancer Gene Therapy. Adv Mater. 2016;28(48):10613–22. · DOI
  187. Luo Z, Dai Y, Gao H. Development and application of hyaluronic acid in tumor targeting drug delivery. Acta Pharm Sin B. 2019;9(6):1099–112. · DOI · Paper page
  188. Li H, et al. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol Lett. 2017;14(5):5865–70.
  189. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res. 1997;57(4):778–83.
  190. Moreira AM et al. The Extracellular Matrix: an accomplice in gastric Cancer Development and Progression. Cells, 2020. 9(2). · DOI
  191. Liu Y, et al. Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer. Front Immunol. 2022;13:1016817. · DOI
  192. Mohan V, Das A, Sagi I. Emerging roles of ECM remodeling processes in cancer. Semin Cancer Biol. 2020;62:192–200. · DOI
  193. Sung JY, Cheong JH. The Matrisome is Associated with metabolic reprograming in stem-like phenotypes of gastric Cancer. Cancers (Basel), 2022. 14(6). · DOI
  194. Moreira AM, et al. Proteomic identification of a gastric tumor ECM signature Associated with Cancer Progression. Front Mol Biosci. 2022;9:818552. · DOI · Paper page
  195. Jang M, et al. Increased extracellular matrix density disrupts E-cadherin/β-catenin complex in gastric cancer cells. Biomater Sci. 2018;6(10):2704–13. · DOI
  196. Acerbi I, et al. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb). 2015;7(10):1120–34. · DOI
  197. Kuczek DE, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7(1):68. · DOI
  198. Patel A, Sant S. Hypoxic tumor microenvironment: opportunities to develop targeted therapies. Biotechnol Adv. 2016;34(5):803–12. · DOI
  199. Nelson DA, et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 2004;18(17):2095–107. · DOI
  200. Saito G, Swanson JA, Lee K-D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev. 2003;55(2):199–215. · DOI · Paper page

200 of 575 shown

Cited by

Sorted by citations

See all 373

Metadata

Authors
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., Wang, L., Sethi, G., Tergaonkar, V., Tay, F., Yuan, Z., & Han, P.
Venue
Journal of Hematology & Oncology
Publisher
Springer Science and Business Media LLC
Published
2024-04-02
Volume
17
Issue
1
ISSN
1756-8722
DOI
10.1186/s13045-024-01535-8
PMC
PMC10986145
Cited by
373
References
36
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review